These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

320 related items for PubMed ID: 23556452

  • 21. Role of TDM-based dose adjustments for taxane anticancer drugs.
    Muth M, Ojara FW, Kloft C, Joerger M.
    Br J Clin Pharmacol; 2021 Feb; 87(2):306-316. PubMed ID: 33247980
    [Abstract] [Full Text] [Related]

  • 22. The role of taxanes in the treatment of breast cancer.
    Capri G, Tarenzi E, Fulfaro F, Gianni L.
    Semin Oncol; 1996 Feb; 23(1 Suppl 2):68-75. PubMed ID: 8614849
    [Abstract] [Full Text] [Related]

  • 23. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
    Ward S, Simpson E, Davis S, Hind D, Rees A, Wilkinson A.
    Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394
    [Abstract] [Full Text] [Related]

  • 24. Drug evaluation: Bay-59-8862.
    Eckstein JW.
    IDrugs; 2004 Jun; 7(6):575-81. PubMed ID: 15197663
    [Abstract] [Full Text] [Related]

  • 25. Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice.
    Sharma A, Straubinger RM, Ojima I, Bernacki RJ.
    J Pharm Sci; 1995 Dec; 84(12):1400-4. PubMed ID: 8748320
    [Abstract] [Full Text] [Related]

  • 26. Pharmacogenetics of taxanes: impact of gene polymorphisms of drug transporters on pharmacokinetics and toxicity.
    Jabir RS, Naidu R, Annuar MA, Ho GF, Munisamy M, Stanslas J.
    Pharmacogenomics; 2012 Dec; 13(16):1979-88. PubMed ID: 23215890
    [Abstract] [Full Text] [Related]

  • 27. Oral efficacy and bioavailability of a novel taxane.
    Polizzi D, Pratesi G, Monestiroli S, Tortoreto M, Zunino F, Bombardelli E, Riva A, Morazzoni P, Colombo T, D'Incalci M, Zucchetti M.
    Clin Cancer Res; 2000 May; 6(5):2070-4. PubMed ID: 10815934
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Docetaxel-Loaded PLGA Nanoparticles Improve Efficacy in Taxane-Resistant Triple-Negative Breast Cancer.
    Bowerman CJ, Byrne JD, Chu KS, Schorzman AN, Keeler AW, Sherwood CA, Perry JL, Luft JC, Darr DB, Deal AM, Napier ME, Zamboni WC, Sharpless NE, Perou CM, DeSimone JM.
    Nano Lett; 2017 Jan 11; 17(1):242-248. PubMed ID: 27966988
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Taxane containing regimens for metastatic breast cancer.
    Ghersi D, Wilcken N, Simes J, Donoghue E.
    Cochrane Database Syst Rev; 2005 Apr 18; (2):CD003366. PubMed ID: 15846659
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Second generation taxanes: from the natural framework to the challenge of drug resistance.
    Ferlini C, Ojima I, Distefano M, Gallo D, Riva A, Morazzoni P, Bombardelli E, Mancuso S, Scambia G.
    Curr Med Chem Anticancer Agents; 2003 Mar 18; 3(2):133-8. PubMed ID: 12678907
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.